This compound is a pharmaceutical intermediate specifically used in the manufacturing of impurities related to afatinib. It features a complex quinazoline core with multiple functional groups including aromatic rings, ether linkages, and an amide bond, reflecting its role in advanced organic synthesis for pharmaceutical development.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 2413212-23-2
N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-3,4-bis(dimethylamino)butanamide
Pharmaceutical reference impurity standard
(S)-N1-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-((TETRAHYDROFURAN-3-YL)OXY)QUINAZOLIN-6-YL)-N2,N2-DIMETHYLOXALAMIDE
pharmaceutical intermediate
N-(3,4-Difluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine
Pharmaceutical intermediate for afatinib impurities
Afatinib Impurity 18
Pharmaceutical impurity reference standard
(S,E)-2-((3-Chloro-4-fluorophenyl)(6-(4-(dimethylamino)but-2-enamido)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-4-yl)amino)malonic acid
Pharmaceutical intermediate for Afatinib impurities
2306254-34-0free base
pharmaceutical intermediate
(4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methanol dihydrochloride
Pharmaceutical intermediate
Afatinib Impurity AFT-8
Active pharmaceutical ingredient impurity reference
(3R)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3R)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)-3-hydroxybutanamide
IQINQKMQCQYKAD-HZPDHXFCSA-N
CN(C)C[C@@H](CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4CCOC4)O
—